Good
Mostly Aligned
Patient Risk:
Low
Summary
Most mechanistic and identity claims align with the provided label sections (11 and 12.1). Several detailed mechanistic characterizations (e.g., JH2/pseudokinase domain naming, ATP-site exclusion, and structural/pocket-fit comparisons) are not explicitly supported by the provided label text.
Category Scores
Accurate Statements
Sotyktu is the brand name for deucravacitinib.
Section 11 DESCRIPTION: 'SOTYKTU (deucravacitinib) tablets...'
Deucravacitinib is an oral small-molecule.
Section 11 DESCRIPTION: 'for oral administration' and chemical description of deucravacitinib
Deucravacitinib targets TYK2 (tyrosine kinase 2).
Section 12.1 MECHANISM OF ACTION: 'Deucravacitinib is an inhibitor of tyrosine kinase 2 (TYK2)'
Deucravacitinib changes TYK2 signaling involved in inflammatory pathways.
Section 12.1: allosteric inhibition of receptor-mediated TYK2 activation and downstream STAT activation
Deucravacitinib binds to the regulatory domain of TYK2 and stabilizes an inhibitory interaction between regulatory and catalytic domains.
Section 12.1: 'Deucravacitinib binds to the regulatory domain of TYK2, stabilizing an inhibitory interaction...'
Unsupported Statements
Deucravacitinib binds directly to the JH2 (pseudokinase) domain of TYK2.
Section 12.1 provided states binding to the regulatory domain of TYK2 but does not explicitly name the JH2 (pseudokinase) domain.
Deucravacitinib acts as a JH2-domain binder rather than binding the ATP (catalytic) site in TYK2’s kinase domain.
Provided label text describes allosteric inhibition and binding to the regulatory domain, but does not explicitly contrast with ATP/catalytic-site binding.
Deucravacitinib is described as a TYK2 pathway-targeted therapy rather than a classic ATP-competitive kinase inhibitor.
Provided label text does not use 'pathway-targeted therapy' phrasing or explicitly characterize the drug as 'not a classic ATP-competitive kinase inhibitor.'
Deucravacitinib is a small molecule designed to fit a specific receptor pocket on TYK2’s JH2 domain.
The provided label sections do not describe 'receptor pocket' fitting/design or specifically reference the JH2 domain.
Deucravacitinib’s structure differs from ATP-competitive TYK2 inhibitors, which are built to occupy the kinase active site.
The provided label sections do not include structural comparisons versus ATP-competitive TYK2 inhibitors or active-site occupation statements.
Contradictions
Important Omissions
No label-aligned omission applicable to evaluate, because the claims provided are limited to identity/mechanism/targeting; no dosing, contraindications, boxed warnings, or safety claims were made that could be assessed for omission.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims are mechanistic/targeting descriptions and do not include dosing/safety-critical instructions. Main gaps are lack of explicit label support for detailed ATP-site/JH2/structural-pocket characterizations.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several mechanistic details go beyond what the provided label explicitly states (JH2/pseudokinase naming, ATP-site exclusion framing, and structural/pocket-fit comparisons).
Suggested Improvement
Rephrase mechanistic claims to align strictly with the label wording: binding to the regulatory domain of TYK2 and resulting allosteric inhibition of receptor-mediated activation and downstream STAT activation, without asserting specific JH2-domain terminology or ATP/active-site contrasts not stated in the provided label.